SEC Form 4 · accession 0001144204-18-021207
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Garanzini
Officer — Chief Commercial Officer
Period of report
Apr 17, 2018
Accepted (ET)
Apr 18, 2018 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 17, 2018 | P$0 | 156,250 | — | A | 171,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants (right to buy)F1 | $0.32 | Apr 17, 2018 | P | 156,250 | A | Apr 17, 2018 | Apr 17, 2023 | Common Stock | 156,250 | 156,250 | D |
Explanation of responses
- F1The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32.